regulus therapeutics inc
(RGLS:Consolidated Issue listed on NASDAQ Global Market)
Kleanthis G. Xanthopoulos Ph.D.
Chief Executive Officer, President, Principal Financial & Accounting Officer and Director, Regulus Therapeutics Inc.
|Age||Total Calculated Compensation||This person is connected to 137 board members in 6 different organizations across 11 different industries.|
See Board Relationships
As of Fiscal Year 2013
Dr. Kleanthis G. Xanthopoulos, Ph.D., has been the Chief Executive Officer and President of Regulus Therapeutics Inc., since January 2009 and also has been its Principal Financial & Accounting Officer since June 21, 2013. Dr. Xanthopoulos serves as the Managing Director of Life Science Investments at Novera Optics, Inc. He serves as Senior Vice President at Isis Pharmaceuticals, Inc. He serves as a Member of the Executive Board at BIOCOM, Inc. He founded Sente, Inc. ...
3545 John Hopkins CourtPhone: 858-202-6300
San Diego, California 92121
Board Members Memberships*
Founder and Director
Former Director and Member of Audit Committee
Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Chairman of the Board
Director, Member of Compensation Committee and Member of Nominating & Corporate Governance Committee
University of Thessaloniki
|Ali Mortazavi||Chief Executive and Director|
Silence Therapeutics plc
|Peter French B.Sc, M.Sc, Ph.D., MBA||Chief Executive Officer, Managing Director and Director|
Benitec Biopharma Limited
|Hans G. C. P. Schikan||Chief Executive Officer and Member of Management Board|
Prosensa Holding N.V.
|Mark W. Schwartz Ph.D.||Chief Executive Officer, President and Director|
Galena Biopharma, Inc.
|Mark J. Murray Ph.D.||Chief Executive Officer, President and Director|
Tekmira Pharmaceuticals Corporation
|$377.5K||Compensation as of Fiscal Year 2013.|